10
|
Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol 2017; 35:1641-1649. [PMID: 28319436 PMCID: PMC5548226 DOI: 10.1200/jco.2016.72.0722] [Citation(s) in RCA: 501] [Impact Index Per Article: 71.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Purpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer radiotherapy versus no radiotherapy in 75 trials yielded rate ratios (RRs) for second primary cancers and cause-specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality. Smoking status was unavailable. Third, the lung or heart ERRs per Gy in the trials and the 2010 to 2015 doses were combined and applied to current smoker and nonsmoker lung cancer and cardiac mortality rates in population-based data. Results Average doses from 647 regimens published during 2010 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart. The median year of irradiation was 2010 (interquartile range [IQR], 2008 to 2011). Meta-analyses yielded lung cancer incidence ≥ 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis of 134 cancers, indicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose. For cardiac mortality, RR was 1.30 (95% CI, 1.15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths. Detailed analyses indicated 0.04 (95% CI, 0.02 to 0.06) ERR per Gy whole-heart dose. Estimated absolute risks from modern radiotherapy were as follows: lung cancer, approximately 4% for long-term continuing smokers and 0.3% for nonsmokers; and cardiac mortality, approximately 1% for smokers and 0.3% for nonsmokers. Conclusion For long-term smokers, the absolute risks of modern radiotherapy may outweigh the benefits, yet for most nonsmokers (and ex-smokers), the benefits of radiotherapy far outweigh the risks. Hence, smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy risk.
Collapse
Affiliation(s)
- Carolyn Taylor
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Candace Correa
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Frances K. Duane
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Marianne C. Aznar
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Stewart J. Anderson
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Jonas Bergh
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - David Dodwell
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Marianne Ewertz
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Richard Gray
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Reshma Jagsi
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Lori Pierce
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Kathleen I. Pritchard
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Sandra Swain
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Zhe Wang
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Yaochen Wang
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Tim Whelan
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Richard Peto
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Paul McGale
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - for the Early Breast Cancer Trialists’ Collaborative Group
- Carolyn Taylor, Frances K. Duane, David Dodwell, Richard Gray, Zhe Wang, Yaochen Wang, Richard Peto, and Paul McGale, University of Oxford, Oxford, United Kingdom; Candace Correa, Regional Cancer Center, Utica, NY; Marianne C. Aznar, Rigshospitalet, Copenhagen; Marianne Ewertz, Odense University Hospital, Odense, Denmark; Stewart J. Anderson, University of Pittsburgh, Pittsburgh, PA; Jonas Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden; Reshma Jagsi and Lori Pierce, University of Michigan, Ann Arbor MI; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto; Tim Whelan, Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; and Sandra Swain, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| |
Collapse
|